BEARINGPOINT
Management and technology consultancy BearingPoint reports full-year revenues of €1.017 billion for 2023, a jump in year-on-year growth of 18%. The firm saw its bookings grow by 21% and delivered more than 1,800 projects in 32 countries. To support its growth, BearingPoint increased its workforce by 15% to more than 6,000 employees at the end of the year. For 2024, BearingPoint plans to hire more than 1,600 people as it accelerates its strategy and continues to expand globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240205345183/en/
Kiumars Hamidian, Managing Partner of BearingPoint. (Photo: Business Wire)
“2023 was a breakout year for BearingPoint,” said Kiumars Hamidian, Managing Partner of BearingPoint. “We reached our €1 billion in revenue target, and we did it sustainably, with a healthy growth position. We continue to see increasing demand for our services, especially our transformation programs and IP-driven digital assets. Growing demand is behind our expanding workforce, and we will continue strategic acquisitions in 2024 as we expand globally. I would like to thank all our amazing people and clients who made this success possible.”
Strategic acquisitions and global expansion
In 2023, BearingPoint completed five strategic acquisitions to enhance and strengthen its portfolio, particularly in the areas of sustainability (Korkia), Salesforce expertise (Smplicity), asset-backed securities (ABS) (TXS Securitization), and end-to-end services for IFS software and solutions through Arcwide, the joint venture of BearingPoint and IFS (bytics Group and Cedar Bay).
BearingPoint’s record hiring in 2023 was also due to expanding its expertise and services globally, especially in the US and China. In the US alone, BearingPoint achieved a revenue growth of 34%.
With more than 440 people and a strong revenue growth of 28%, the development of the Products business unit was another highlight for BearingPoint.
Continued investment in innovation, artificial intelligence and sustainability
BearingPoint continued to invest heavily in its innovative products and services and launched a generative AI hub, paving the way for businesses to unlock the transformative power of artificial intelligence. As one of the first consultancies BearingPoint published an ethical statement on the sustainable and responsible use of AI in cooperation with clients. The consultancy also set up an AI business task force early in 2023 and developed over 250 use cases last year. BearingPoint is delivering innovative solutions for its clients, including implementing a global GenAI vision for a top retail chain, creating an AI banking avatar for a large international bank, simplifying daily police work with an AI for a police department, and automating the creation of annual reports for an NGO.
BearingPoint has also supported many clients on their sustainability and decarbonization journeys, through integrated sustainability advisory and products as well as launching innovative new services including the BearingPoint Sustainability Maturity Assessment, the ESG Data Hub and the I Care Academy. BearingPoint has provided clients with streamlined ESG reporting support and enhanced sustainability transformation programs. Moreover, the firm invested more than 1,000 consulting days in CSR activities and ran numerous Climate Fresk workshops throughout the year.
People development is a top priority
In 2023, BearingPoint appointed 27 new Partners to the firm and promoted 1,398 people, the largest-ever cohort, reflecting the strength of the organization and its confidence in the future. BearingPoint made record investments in learning and people development and delivered an all-time-high of 260,000 training hours. BearingPoint provides a range of programs, such as Be.Oxford Academy, Be.School, Female Leadership, and the Yale Leadership Program. Over 2,200 people participated in these programs in 2023, a year which saw BearingPoint also open its Be.Campus in Brussels, where the firm will deliver even more trainings in 2024.
2024 – Strategy acceleration continues
In 2024, BearingPoint wants to outperform the market again and accelerate its strategy execution further, planing a double-digit organic revenue growth. In addition, the consultancy sees more strategic M&A activities and investments in developing its consulting and products portfolio in 2024, especially in focus areas such as sustainability and in key geographies such as the US. BearingPoint also said its joint venture Arcwide will continue to expand to become the IFS delivery partner of choice for enterprise organizations worldwide.
“As we look towards the future, BearingPoint is in an excellent position to grow and expand further. We are faithful to our values, empower people to succeed, and create lasting outcomes for our clients, society, and the planet,” said Kiumars Hamidian.
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
X: @BearingPoint
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240205345183/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom